Arbutus BiopharmaABUS 51 Net Current Asset Value is $1.32 as of Mar. 2026, which is 71% below its 10-year median of 4.58. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $51.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, Arbutus Biopharma ranks better than 59.51% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Arbutus Biopharma's net current asset value per share for the quarter that ended in Mar. 2026 was $1.32.
The historical rank and industry rank for Arbutus Biopharma's Net Current Asset Value or its related term are showing as below:
ABUS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.25 Med: 4.58 Max: 18.79
Current: 3.64
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Arbutus Biopharma was 18.79. The lowest was 2.25. And the median was 4.58.
ABUS's Price-to-Net-Current-Asset-Value is ranked better than 59.51% of 946
companies
in the Biotechnology industry
Industry Median: 4.87
vs ABUS: 3.64
Arbutus Biopharma (NAS:ABUS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Arbutus Biopharma Net Current Asset Value Related Terms
Arbutus Biopharma Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABUS vs EVMN, ANNX, TBPH: Net Current Asset Value Comparison
For the Biotechnology subindustry, Arbutus Biopharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.32 mean?
Arbutus Biopharma (ABUS) has a Net Current Asset Value of $1.32 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Arbutus Biopharma and its competitors. This is 71% below median its historical median of 4.58. Over the past decade, Arbutus Biopharma's Net Current Asset Value has ranged from 2.25 to 18.79. According to the industry distribution chart, Arbutus Biopharma ranks #383 out of 946 companies in the Biotechnology industry, placing it in the top 40.5%.
Is Arbutus Biopharma's Net Current Asset Value too high?
Arbutus Biopharma's current Net Current Asset Value of $1.32 is 71% below median its 10-year median of 4.58. Over the past 10 years, this metric has ranged from a low of 2.25 to a high of 18.79. The Biotechnology industry median Net Current Asset Value is 4.87. Arbutus Biopharma's value of $1.32 is 72.9% below this industry median. Based on the distribution chart, Arbutus Biopharma ranks #383 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Net Current Asset Value compare to EVMN and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #383 out of 946 companies for Net Current Asset Value. This puts Arbutus Biopharma in the upper half of its industry. The industry median Net Current Asset Value is 4.87. Arbutus Biopharma's value of $1.32 is 72.9% below this benchmark. Historically, Arbutus Biopharma's own Net Current Asset Value has ranged from 2.25 to 18.79 over the past decade. While the company's 10-year median is 4.58 vs. the industry median of 4.87, Arbutus Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.87, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Net Current Asset Value of $1.32 is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Net Current Asset Value is $1.32, which is 71% below median its own 10-year median of 4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.25, compared to a current price of $4.80 — trading 90.6% below its estimated fair value. The current Net Current Asset Value is $1.32, which is 71% below median its 10-year median of 4.58 and 72.9% below the Biotechnology industry median of 4.87. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Net Current Asset Value is $1.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.80 is trading 90.6% below its estimated GF Value™ of $51.25.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Net Current Asset Value: $1.32 (71% below median its 10-year median of 4.58)
GF Value™: $51.25 vs. price of $4.80 (90.6% below fair value)
Industry Position: 72.9% below the Biotechnology median (#383 of 946)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
